Dosing & Uses
Parkinson Disease
Pending FDA approval for treatment of motor fluctuations in patients with advanced Parkinson disease (PD)
Next:
Pharmacology
Mechanism of Action
Parkinson disease symptoms are associated with a loss of dopamine neurons in the brain
Foscarbidopa and foslevodopa are prodrugs of carbidopa and levodopa with increased solubility; this allows for a highly concentrated solution and enables administration by a minimally invasive continuous SC infusion to provide sustained therapeutic levels of plasma levodopa
Carbidopa
- Inhibits aromatic amino-acid decarboxylase in peripheral tissues; this, in turn, inhibits peripheral breakdown of levodopa, thereby increasing availability of levodopa at blood-brain barrier and allowing a lower levodopa dose
Levodopa
- Levodopa is a metabolic precursor of dopamine, a neurotransmitter depleted in Parkinson disease; crosses blood-brain barrier to be converted by striatal enzymes to dopamine
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
